Dr. Fadi Farha

Feinstein Institutes for Medical Research, USA

Research Scientist

Email: Zhijian.hu56@gmail.com

Qualifications

2019 Ph.D., University of Arkansas, USA.

2012 MMed., Huazhong University of Science and Technology (HUST), China.

2009 MBBS., Huazhong University of Science and Technology (HUST), China.

Publications (Selected)

1. Zong G., Hu Z., Duah KB., Andrews LE., Zhou J., O’Keefe S., Whisenhunt L., Shim JS., Du Y., High S., Shi W.Q. Ring Expansion Leads to a More Potent Analogue of Ipomoeassin F. J. Org. Chem. 2020, 85(24):16226–16235. (Co-First author).
2. Bissoondial TL.; Han Y.; Mullan S.; Pabla AK.; Spahn K.; Shi S.; Zheng L.; Zhou P.; Jiang K.; Prakash N.; Bhutkar S.; Ali Q.; Li J.; Hu Z.; Pellicano AJ.; Goldberg ID.; Narayan P. Liver biopsy hydroxyproline content is a diagnostic for hepatocellular carcinoma in murine models of nonalcoholic steatohepatitis. Diagnostics (Basel). 2020, 10(10):784.
3. Liu M.; Dalvi A.; Dalapati S.; Prakash N.; Hu Z.; Zhou P.; Jiang K.; Pellicano A.; Goldberg I.; Narayan P. Targeting collagen type III in proteinuric kidney disease: Informing drug potential using the Jaccard– Tanimoto Index. Processes 2020, 8 (8): 996.
4. Liao K.; Pellicano A.; Jiang K.; Prakash N.; Li J.; Bhutkar.; Hu Z.; Ali Q.; Goldberg I.; Narayan P. Glycerol-3- phosphate acyltransferase1 is a model-agnostic node in nonalcoholic fatty liver disease: Implications for drug development and precision medicine. ACS Omega. 2020, 5(29): 18465–18471.
5. Zong G.; Hu Z.; O’Keefe S.; Tranter D.; Iannotti MJ.; Baron L.; Hall B.; Corfield K.; Paatero AO.; Henderson MJ.; Roboti P.; Zhou J.; Sun X.; Govindarajan M.; Rohde JM.; Blanchard N.; Simmonds R.; Inglese J.; Du Y.; Demangel C.; High S.; Paavilainen VO.; Shi W.Q. Ipomoeassin F Binds Sec61α to Inhibit Protein Translocation. J. Am. Chem. Soc. 2019, 141(21): 8450 - 8461. (Co-first author).
6. Zong G.; Sun X.; Bhakta R1.; Whisenhunt L.; Hu Z.; Wang F.; Shi WQ. New insights into structure-activity relationship of ipomoeassin F from its bioisosteric 5-oxa/aza analogues. Eur J. Med. Chem. 2018,144:751 - 757.
7. Zong G; Hirsch M.; Mondrik C.; Hu Z.; Shi W. Q. Design, Synthesis and Biological Evaluation of Fucose- Truncated Monosaccharide Analogues of Ipomoeassin F. Bioorg. Med. Chem. Lett. 2017, 12(27): 2752 - 2756.
8. Zong G.; Whisenhunt, L.; Hu Z.; Shi W. Q. Synergistic Contribution of Tiglate and Cinnamate to Cytotoxicity of Ipomoeassin F. J. Org. Chem. 2017, 82(9): 4977 - 4985.
9. Zong G.; Aljewari H.; Hu Z.; Shi, W. Q. Revealing the Pharmacophore of Ipomoeassin F through Molecular Editing. Org. Lett. 2016, 18(7): 1674 - 1677. • Gao J.; Shi W.; Hu Z.; Bai L.; Chai X. Hepatectomy for hepatolithiasis among patients with a history of biliary surgery. Int. J. Clin. Exp. Med. 2016, 9(7):13184 - 13189 .
10. Zong G.; Barber, E.; Aljewari H.; Zhou J.; Hu Z.; Du Y.; Shi W. Q. Total Synthesis and Biological Evaluation of Ipomoeassin F and its Unnatural 11R-Epimer. J. Org. Chem. 2015, 80(18): 9279 - 9291.
11. Hu Z.; Chai X.; Bai L.; Wu J.; Preoperative Assessment and Management of Geriatric Bile Duct Reoperation, Journal of Hepatobiliary Surgery, 2012, 20(2): 131 - 134.
12. Hu Z.; Bai L.; Chai X.; Pathogenesis of Hepatopulmonary Syndrome, International Journal of Surgery, 2012, 39(5): 331 - 335.
13. Hu Z.; Bai L.; Chai X.; The Current Diagnosis and Therapy of Hepatopulmonary Syndrome, International Journal of Surgery, 2012, 39(1): 34 - 39.
14. Bai L.; Chai X.; Hu Z.; Xiansong Feng, Assessment and Management of Biliary Tract Re-operation Accompanied with Hepatocirrhosis and Portal Hypertension, Journal of Hepatopancreatobiliary Surgery, 2011, 23(3): 202 - 204.
15. Bai L.; Chai X.; Hu Z.; One case of recurrence of liver echinococcosis found in the inland, Journal of Hepatobiliary Surgery, 2011, 19(3): 240.
16. Hu Z.; Chai X.; Bai L.; Ye L.; Feng X.; Analysis of 11 Choledochocyst Re-operation, Journal of Hepatobiliary Surgery, 2011, 19(3): 174 - 176.

Profile Details

https://scholar.google.com/citations?user=uzvxwNQAAAAJ&hl=zh-CN